Skip to main content
Fig. 7 | Breast Cancer Research

Fig. 7

From: Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Fig. 7

Upregulation of CXCR4 in residual disease of breast cancer. A CXCR4 protein in 72 residual tumor tissues and 112 primary tumor samples from breast cancer patients was analyzed using RPPA. B CXCR4 protein in residual HER2 + breast cancer after treatment with trastuzumab and chemotherapy compared with primary HER2 + breast cancer. C CXCR4 expression in breast cancer tissues was confirmed with western blot. D Representative human HER2 + breast cancer residual breast tumor tissue samples with immunohistochemical staining. Original magnification, 200x. E Serum samples from breast cancer patients or healthy women were measured for SDF-1α with ELISA. Data were analyzed using t-test

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us